LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova, TurboCBD, ChrgD+ and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CF:LXX.

$2.87  +0.12 (4.36%)
As of 01/24/2023 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Packaged Foods
Index country:  Canada
Country of incorporation:  
IPO date:  10/10/2006
Outstanding shares:  5,950,998
Average volume:  12,969
Market cap:   $16,365,245
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy